As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults ... a chronic debilitating and relapsing skin condition, BP is driven by type 2 ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

Dupixent is a targeted medicine developed for treating bullous pemphigoid (BP), a chronic skin disease marked by intense itch and blisters. What significant results did the Dupixent trial achieve?

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...

Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...